AbbVie AbbVie

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Huadong Medicine","sponsor":"Ashvattha Therapeutics","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ashvattha Therapeutics Announces $69 Million in Series B Financing and up to $45M Exclusive License Agreement with Huadong to Advance Hydroxyl Dendrimer-Based Precision Medicines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Huadong Medicine","sponsor":"CARsgen Therapeutics","pharmaFlowCategory":"D","amount":"$181.3 million","upfrontCash":"$29.6 million","newsHeadline":"CARsgen, Huadong Medicine Ink Deal To Sell CAR T-cell Product In China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Huadong Medicine","sponsor":"Arcutis Biotherapeutics","pharmaFlowCategory":"D","amount":"$94.2 million","upfrontCash":"$30.0 million","newsHeadline":"Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Huadong Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUADONG MEDICINE Reports Positive Phase I Results for GLP-1 Agonist HDM1002","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Huadong Medicine

    Menu

    Huadong Medicine

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Huadong Medicine

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              HUADONG MEDICINE Reports Positive Phase I Results for GLP-1 Agonist HDM1002

              Details:

              HDM1002 is an innovative potent small molecule drug, highly selective full agonist of the GLP-1 receptor. It is being developed for Type 2 Diabetes Mellitus.

              Lead Product(s): HDM1002

              Therapeutic Area: Endocrinology Product Name: HDM1002

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 26, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Huadong Medicine

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia

              Details:

              Under the collaboration, Huadong will receive license for both the cream and foam formulations of topical Zoryve (roflumilast), a next generation PDE4 inhibitor, for multiple dermatological conditions including plaque psoriasis, seborrheic dermatitis, and atopic dermatitis.

              Lead Product(s): Roflumilast

              Therapeutic Area: Dermatology Product Name: Zoryve

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Arcutis Biotherapeutics

              Deal Size: $94.2 million Upfront Cash: $30.0 million

              Deal Type: Collaboration August 10, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Huadong Medicine

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ashvattha Therapeutics Announces $69 Million in Series B Financing and up to $45M Exclusive License Agreement with Huadong to Advance Hydroxyl Dendrimer-Based Precision Med...

              Details:

              Under the terms of the exclusive licensing agreement, Huadong will advance research and development costs for Ashvattha’s hydroxyl dendrimer clinical candidates, OP-101, D-4517.2 and OP-801, and for additional preclinical candidates.

              Lead Product(s): Dendrimer N-acetyl-cysteine

              Therapeutic Area: Infections and Infectious Diseases Product Name: OP-101

              Highest Development Status: Phase II Product Type: Large molecule

              Recipient: Ashvattha Therapeutics

              Deal Size: $45.0 million Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement April 27, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Huadong Medicine

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CARsgen, Huadong Medicine Ink Deal To Sell CAR T-cell Product In China

              Details:

              CT053 (zevorcabtagene autoleucel), is a fully human, autologous BCMA CAR T-cell product candidate for the treatment of relapsed/refractory multiple myeloma (R/R MM).

              Lead Product(s): Zevorcabtagene Autoleucel

              Therapeutic Area: Oncology Product Name: CT053

              Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

              Recipient: CARsgen Therapeutics

              Deal Size: $181.3 million Upfront Cash: $29.6 million

              Deal Type: Collaboration January 16, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Moehs Group, a reference company in the production of pharmaceutical active ingredients.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY